BioArctic AB (publ) (BRCTF)
OTCMKTS · Delayed Price · Currency is USD
33.14
0.00 (0.00%)
Feb 11, 2026, 4:00 PM EST
BioArctic AB Revenue
BioArctic AB had revenue of 133.35M SEK in the quarter ending September 30, 2025, with 74.00% growth. This brings the company's revenue in the last twelve months to 1.92B, up 1,046.52% year-over-year. In the year 2024, BioArctic AB had annual revenue of 257.35M, down -58.22%.
Revenue (ttm)
1.92B SEK
Revenue Growth
+1,046.52%
P/S Ratio
15.59
Revenue / Employee
15.71M SEK
Employees
122
Market Cap
3.17B USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 257.35M | -358.64M | -58.22% |
| Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
| Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
| Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
| Dec 31, 2020 | 65.21M | -217.74M | -76.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
BioArctic AB News
- 6 days ago - Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025 - PRNewsWire
- 2 months ago - Leqembi included in China's commercial insurance innovative drug list - PRNewsWire
- 2 months ago - New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment - PRNewsWire
- 2 months ago - Eisai Announces Filing Of New Drug Application For Leqembi In Japan - Nasdaq
- 3 months ago - New data on lecanemab to be presented at CTAD conference - PRNewsWire
- 3 months ago - BioArctic AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Leqembi® approved for IV maintenance treatment in the United Kingdom - PRNewsWire
- 3 months ago - BioArctic AB (publ) (BRCTF) Q3 2025 Earnings Call Transcript - Seeking Alpha